Last reviewed · How we verify
Disorder of eye
Approved treatments
- Solu-Cortef · Pfizer
- Cortifoam · Pfizer
- Cortone
- Celestone Soluspan
- Decadron · Generic (originally Merck)
- Medrol · Generic (originally Upjohn/Pfizer)
Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions. - Cortef · Generic (originally Merck/Upjohn)
- Rodinolone
- Betametasone
Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system. - Cortisol · University of Zurich
- Prelone · Generic (originally Schering)
- prednisolon · Hannover Medical School
- Methylprednisolon · Leiden University Medical Center
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Disorder of eye patent landscape — cliff calendar, originator estates, attackable patents
- Disorder of eye treatment landscape brief
- Disorder of eye treatment updates RSS
Frequently asked questions about Disorder of eye
What drugs treat Disorder of eye?
Tracked treatments include Solu-Cortef, Cortifoam, Cortone, Celestone Soluspan, Decadron, Medrol, Cortef, Rodinolone.
What is the treatment for Disorder of eye?
Standard treatment for Disorder of eye includes Solu-Cortef, Cortifoam, Cortone, Celestone Soluspan, Decadron. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Disorder of eye patent cliff · Disorder of eye CI report
- Treatment: Solu-Cortef · Pfizer
- Treatment: Cortifoam · Pfizer
- Treatment: Cortone
- Treatment: Celestone Soluspan
- Treatment: Decadron · Generic (originally Merck)
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing